A Review of The State of Drug Development for uncommon Diseases and its Future Potential-Reference-Cited by-同舟云学术

A Review of The State of Drug Development for uncommon Diseases and its Future Potential

Published:2024-05-15 Issue: Volume: Page:2405-2408
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Kumar A. Sathish¹,Reddy P. Bhaskara²

Affiliation:

1. Associate Professor, Department of EEE, Holy Mary Institute of Technology and Science, Hyderabad, Telangana, India.

2. Professor and Director, Department of Electronics and Communication Engineering, Holy Mary Institute of Technology and Science, Hyderabad, Telangana, India.

Abstract

This article discusses the development of drugs for uncommon diseases as well as the future prospects for these drugs. When developing treatments for uncommon diseases, there are several challenges that must be overcome. Among them are limited patient populations, a lack of understanding of uncommon diseases, and regulatory hurdles. Regulatory incentives and advancements in drug development are discussed in addition to the use of biomarkers and repurposing existing drugs. Patients suffering from uncommon diseases need innovation and collaboration.

Publisher

A and V Publications

Reference19 articles.

1. Epps C, Bax R, Croker A, et al. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Ther Innov Regul Sci. 2022; 56(6): 964-975. doi:10.1007/s43441-022-00409-w

2. Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021; 16(1). doi:10.1186/s13023-021-01901-6

3. Pontes C, Fontanet JM, Vives R, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: Methodological uncertainties. Orphanet J Rare Dis. 2018; 13(1). doi:10.1186/s13023-018-0926-z

4. Casamento K, Laverty A, Wilsher M, et al. Assessing the feasibility of a web-based registry for multiple orphan lung diseases: The Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience. Orphanet J Rare Dis. 2016; 11(1). doi:10.1186/s13023-016-0389-z

5. Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med. 2019; 179(7): 906-913. doi:10.1001/jamainternmed.2019.0462